We’re improving your experience!

×

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05601726
Title First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients (ODYSSEY)
Acronym ODYSSEY
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Advanced BioDesign
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA

Facility Status City State Zip Country Details
Hôpital de la Timone RECRUITING Marseille 13005 France Details
Hôpital Saint-Louis RECRUITING Paris 75475 France Details
Centre Hospitalier Lyon Sud RECRUITING Pierre-Bénite 69495 France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field